Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Cash (2018 - 2025)

10x Genomics' Change in Cash history spans 8 years, with the latest figure at $41.3 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 176.27% year-over-year to $41.3 million; the TTM value through Dec 2025 reached $129.9 million, up 953.64%, while the annual FY2025 figure was $129.9 million, 953.64% up from the prior year.
  • Change in Cash for Q4 2025 was $41.3 million at 10x Genomics, up from $35.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $112.4 million in Q1 2023 and bottomed at -$276.0 million in Q1 2022.
  • The 5-year median for Change in Cash is -$6.2 million (2023), against an average of -$10.7 million.
  • The largest annual shift saw Change in Cash plummeted 906.61% in 2022 before it skyrocketed 1041.88% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$13.0 million in 2021, then dropped by 9.27% to -$14.2 million in 2022, then surged by 413.77% to $44.5 million in 2023, then tumbled by 221.43% to -$54.1 million in 2024, then skyrocketed by 176.27% to $41.3 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Change in Cash are $41.3 million (Q4 2025), $35.0 million (Q3 2025), and $20.7 million (Q2 2025).